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Summary
Background: TGF-b1 controls many pathophysiological pro-
cesses including tissue homeostasis, fibrosis, and cancer
progression. Together with its latency-associated peptide
(LAP), TGF-b1 binds to the latent TGF-b1-binding protein-1
(LTBP-1), which is part of the extracellularmatrix (ECM). Trans-
mission of cell force via integrins is one major mechanism to
activate latent TGF-b1 from ECM stores. Latent TGF-b1
mechanical activation is more efficient with higher cell forces
and ECM stiffening. However, little is known about the molec-
ular events involved in this mechanical activation mechanism.
Results: By using single-molecule force spectroscopy and
magnetic microbeads, we analyzed how forces exerted on
the LAP lead to conformational changes in the latent complex
that can ultimately result in TGF-b1 release. We demonstrate
the unfolding of two LAP key domains for mechanical
TGF-b1 activation: the a1 helix and the latency lasso, which
together have been referred to as the ‘‘straitjacket’’ that keeps
TGF-b1 associated with LAP. The simultaneous unfolding of
both domains, leading to full opening of the straitjacket at
a force ofw40 pN,was achieved onlywhen TGF-b1was bound
to the LTBP-1 in the ECM.
Conclusions: Our results directly demonstrate opening of
the TGF-b1 straitjacket by application of mechanical force in
the order of magnitude of what can be transmitted by single in-
tegrins. For this mechanism to be in place, binding of latent
TGF-b1 to LTBP-1 is mandatory. Interfering with mechanical
activation of latent TGF-b1 by reducing integrin affinity, cell
contractility, and binding of latent TGF-b1 to the ECMprovides
new possibilities to therapeutically modulate TGF-b1 actions.
Introduction
TGF-b1 is a pleiotropic cytokine that controls cell growth,
inflammation, tissue homeostasis, and immune suppression
in a variety of normal and pathologic adult tissues [1–4].
TGF-b1 is also an important therapeutic target because of its
involvement in the pathogenesis of many disorders, including
organ fibrosis and tumorigenesis. The unsuccessful outcomes
of blocking the already active TGF-b1 in animal experiments
and clinical tests in combination with the risk of uncontrollable
side effects has shifted research toward preventing latent
TGF-b1 activation in a cell type- and activation mechanism-4These authors contributed equally to this work
*Correspondence: boris.hinz@utoronto.caspecific manner [5–11]. TGF-b1 is synthesized as part of a
proprotein that is intracellularly cleaved to produce the small
latent complex (SLC) (Figure 1A). Mature SLC consists of the
TGF-b1 dimer, noncovalently linked to the dimeric latency-
associated peptide (LAP). Most cell types secrete SLC
together with latent TGF-b-binding protein-1 (LTBP-1), consti-
tuting the large latent complex (LLC) [12, 13]. LTBP-1 targets
latent TGF-b1 to the extracellular matrix (ECM) by interacting
with different proteins including fibronectin and fibrillin
[14, 15], generating deposits of latent TGF-b1 accessible for
cell-mediated activation [16–18] (Figure 1A).
Integrins have emerged as central players in TGF-b1 activa-
tion [10, 18, 19]. The expression of cell type-characteristic
integrin sets provides means to interfere with TGF-b1 activa-
tion in a tissue- or cell-specific manner [10, 20–23]. Epithelial
cells activate latent TGF-b1 via integrin avb6 [16, 24], whereas
fibroblasts, devoid of avb6 integrin, appear to promote latent
TGF-b1 activation through integrins avb3, avb8, and avb5
[10, 20–23]. Integrins activate latent TGF-b1 by at least two
different mechanisms [18, 19]. One depends on proteases,
which seem to be guided to the LLC by associating with integ-
rins [10, 17]. The other is independent of proteolysis and
involves transmission of cell traction forces to the LAP moiety
of LLC [17–19].We and others have proposed that ECM-bound
LTBP-1 provides mechanical resistance against cell-mediated
contraction to induce a conformational change in LAP that
leads to liberation of active TGF-b1 [16, 21, 25]. This mechan-
ical mode of action seems to play a major role in stiff fibrotic
scars [18, 21, 26].
To specifically interfere with mechanical TGF-b1 activation,
it is essential to characterize the molecular events involved
in this process. The recently resolved crystal structure of the
SLChas revealed a particular conformation.Whereas the over-
all LAP structure is predicted to be mechanically stable, two
stretches in the molecule are prone to unfolding: the a1 helix
and the latency lasso loop [25]. Together both domains form
a configuration that traps TGF-b1 in the SLC like a ‘‘strait-
jacket’’ [25]. The structure data predict that complete opening
of the straitjacket leads to release of the active TGF-b1 from
LAP [25]. To this end, opening of the straitjacket bymechanical
force has not been experimentally proven.
To provide experimental evidence for a force-induced con-
formational change, we performed force spectroscopy with
the atomic forcemicroscope (AFM), and wemade three funda-
mental discoveries. (1) Mechanical force applied to LAP can
unfold the a1 helix and the latency lasso in the straitjacket.
(2) Simultaneous unfolding of both domains and full opening
of the straitjacket is possible only when LAP is bound to
LTBP-1. (3) In the context of the LLC, fully unraveling the strait-
jacket requires lower forces (w40 pN) than does unfolding of
its individual stretches (w50 pN). Together our data favor an
all-or-nothing snap mechanism of full TGF-b1 release by
mechanical force.
Results
Unfolding of Recombinant SLC and LAP
We first compared the unfolding profiles of recombinant
SLC (TGF-b1-loaded) and LAP (empty) adsorbed onto mica
Figure 1. Unfolding Single Molecules of TGF-b1-Binding
and -Free LAP
(A) TGF-b1 is secreted into the ECM as a LLC, consisting
of the SLC (LAP-TGF-b1) bound to LTBP-1.
(B) Freshly cleaved mica surfaces were coated with
1 mg/cm2 human recombinant SLC or LAP. TGF-b1
activity bioassays were performed with tMLEC cells.
Shown are means 6 SD.
(C) Force-extension traces were obtained after stretch-
ing single LAP or SLC molecules with an AFM tip cova-
lently coated with LAP antibodies. A low pulling speed
of 200 nm/s was selected to prevent unfolding of the
antibodies that deform only at higher pulling rates [50].
Worm-like chain fitting (black lines) was applied to
extract DLc and unfolding forces.
(D and F) DLc values were summarized in frequency
histograms for SLC (D) and LAP (F) and event popula-
tions (red dashed lines) were detected; arrowheads
indicate population maxima.
(E and G) DLc-force pairs for every individual unfolding
event were plotted in bivariate color-coded contour plots
for SLC (E) and LAP (G). Blue represents low and red high
frequency of events.
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2047substrates in the absence of LTBP-1 (Figure 1). TGF-b1-
loading of protein layers was tested by incubating transformed
mink lung epithelial (tMLEC) reporter cells with the liquid
phase from untreated (active TGF-b1) and heat-activated
(total TGF-b1) SLC/LAP-coated samples. Only 15% of the
SLC spontaneously released TGF-b1; no TGF-b1 activity was
measured from LAP-coated mica (Figure 1B). SLC and LAP
were then pulled with AFM probes covalently coated with
anti-LAP monoclonal antibodies. Because forces measured
in AFM depend on the linker flexibility and rate of stressing
[27], we used a loading rate of w10,000 pN/s, comparable
with integrin-ligand interaction studies [28–31]. To determine
the increase in protein contour length (DLc), i.e., the pulling
distance to unfold a protein domain, and to extract unfolding
forces, the worm-like chain model [32] was fitted to individual
unfolding events (Figure 1C).DLc and unfolding forces for all ofthe events were summarized in histograms
(Figures 1D and 1F; Figure S1 available online);
to discriminate event populations, Gaussian
mixture models were fitted to the data.
Fitting the DLc distributions of SLC revealed
three populations centered at 7.1 6 1.6 nm,
11.1 6 2.8 nm, and 17.5 6 7.9 nm (Figure 1D).
Three DLc populations were also determined
for LAP, with maxima at 12.0 6 2.6 nm,
19.0 6 4.5 nm, and 26.9 6 9.5 nm (Figure 1F).
DLc and force cannot be directly correlated
based on the peak order of the histograms.
To retain the information of which force
corresponds to each DLc peak, both parame-
ters of every unfolding event were plotted in
bivariate diagrams; maxima in the frequency
of occurrence of DLc/force pairs appear in
red/yellow (Figures 1E and 1G). Bivariate plots
revealed clear differences between SLC and
LAP unfolding characteristics (Figures 1E
and 1G). SLC unfolding presents one main
event population at 8.1 nm/44.9 pN, whereasLAP unfolding shows three populations at 11.0 nm/46.5 pN,
13.6 nm/74.1 pN, and 12.1 nm/115.5 pN.
Analysis of LAP Structural Domains
These different unfolding characteristics suggest that LAP
attains a stable new conformation after TGF-b1 release. We
subsequently analyzed whether the DLcs measured in re-
combinant LAP and SLC corresponded to the lengths of
important structural domains of the LAP moiety. Recently
published 3D structure data indicate that the LAP moiety is
folded in two principal regions, the straitjacket (Leu30-Pro74)
and the arm (Glu75-Arg278) [25]. Of those, only the a1 helix
(Leu30-Arg58) and the latency lasso (Leu59-Pro74) domains
on the straitjacket are expected to unfold under stretch (Fig-
ure 2A) [25]. Based on these premises, we analyzed whether
the DLcs experimentally measured in recombinant LAP and
Figure 2. Identification of LAP Structural Domains in Force-DLc Plots
(A) Domains predicted to be critical for TGF-b1 storage in LAP include one
a helix of 28 aa (11.2 nm) and an extended loop of 17 aa (6.8 nm) that
connects two a helices (latency lasso). The ensemble of these two domains
(45 aa, 18.0 nm) builds the straitjacket region of LAP.
(B and C) Bivariate DLc-force contour maps for SLC (B) and LAP (C) show all
unfolding events falling in either of the searchwidows defined by the domain
theoretical DLc (dashed lines) 6 10% (dotted lines).
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domains. Expected domain lengths were calculated by multi-
plying the number of residues by 0.4 nm, the average length
of one amino acid (aa) [33]; we allowed a DLc variance
of 610%. To filter for the a1 helix, we scanned for DLc of
11.2 6 1.2 nm (28 6 3 aa); DLc intervals of 6.8 6 0.8 nm
(17 6 2 aa) were defined for the latency lasso. Additionally,
we filtered for DLc of 18.06 1.6 nm (456 4 aa), corresponding
to the whole straitjacket (a1 helix and latency lasso). These
DLc values were also predominant in the SLC and LAP histo-
grams (Figures 1D and 1F). Bivariate plots of DLc-force pairs
were then generated, containing only events with DLc attrib-
uted to these defined domains (Figures 2B and 2C). Unfolding
events with DLc corresponding to the 17 aa latency lasso were
frequent in TGF-b1-loaded SLC (Figure 2B) but virtually absent
in empty LAP (Figure 2C). A pulling force of 47.8 pN was
required to unfold the 6.8 nm latency lasso domain and a
force of 80.8 pN to unfold the 11.2 nm a1 helix domain of
SLC (Table S1). For the few unfolding events identified in
SLC and LAPwith DLcmatching the 18.0 nm-long entire strait-
jacket, forces were lower (w35 pN) than for the individual
domains. Controls performed with bare mica did not produce
any of these events (Figure S3). Pulling with the same antibody
gave different profiles for LAP and SLC; hence, unfolding of
the probing antibody did not contribute to the data. Probing
recombinant LAP and SLC with nonspecific antibodies did
not deliver any unfolding events (unpublished data).
Mechanical Activation of TGF-b1 from the ECM
Cell-mediated mechanical activation of latent TGF-b1 was
shown to require immobilization of the SLC in the ECM via
covalent binding to LTBP-1 [16, 21], which potentially alters
the force needed to unfold SLC.We first established the profile
of force-induced unfolding of LTBP-1 alone to later discrimi-
nate unfolding events in the SLC/LAP moiety of the LLC fromLTBP-1 unfolding events (Figure 3). To specifically target the
AFM probe to LTBP-1 in the ECM, we produced red fluores-
cent LTBP-1 with LTBP-1-mRFP-transfected CHO cells.
Wild-type CHO cells did not express LTBP-1 or LAP-TGF-b1
(Figure 3A). Similar to transfected nontagged LTBP-1, LTBP-
1-mRFP in the ECM was organized in patches and fibrils after
5–7 days of culture (Figure 3A). Whereas LTBP-1 patches were
deposited onto the substrate, fibrils were organized between
cells (Figures 3A and 3C). Fibrils but not patches partially
colocalized with other ECMproteins including fibronectin (Fig-
ure S4, Movie S1), fibrillin-1, and fibrillin-2 (unpublished data).
We removed cells and fibrils with desoxycholate (DOC) (Fig-
ure 3B) before patches of red fluorescent LTBP-1 were tar-
geted with the LTBP-1 antibody-coated AFM probe.
Force-distance profiles were generated for LTBP-1-mRFP,
analyzed, and summarized in histograms as described for
LAP and SLC (Figures 3D, 3E, S1). Four DLc event populations
at 14.8 6 5.0 nm, 26.8 6 8.6 nm, 47.0 6 12.2 nm, and 78.7 6
9.7 nm were identified (Figure 3E). Unfolding forces for
LTBP-1 are summarized in Figure S1. Bivariate plots of DLc-
unfolding force pairs per every single event displayed three
distinct peaks at 16.7 nm/179.4 pN, 22.6 nm/68.2 pN, and
34.5 nm/39.8 pN (Figure 3F). Thus, unfolding of the LTBP-1
resulted in a combination of short stretch-resistant domains
and long flexible domains. Importantly, all these unfolding
events were distinct from those observed in the recombinant
SLC/LAP proteins.
To pull the SLC as an integral part of the LLC, we next
coexpressed LTBP-1 and LAP-TGF-b1 constructs in CHO
cells. Confocal microscopy of immunostained ECM before
(Figure 4A) and after (Figures 4B and 4C) DOC extraction
demonstrated that transfected LAP, TGF-b1, and LTBP-1 all
colocalized. In DOC-extracted ECM, LLC appears as a layer
of w1 mm-thick patches with LAP and TGF-b1 on top of
LTBP-1, colocalizing in the upper part of confocal z-sections
(Figure 4D). Because a substantial fraction of LTBP-1 did not
contain SLC (Figures 4B and 4C, blue), detection of LTBP-1-
mRFP alone was not suitable to guide the AFM probe to the
LLC; therefore, we also provided the SLC with a fluorescent
tag. We ultimately selected a construct with EYFP located
N-terminally to the signal peptide of the LAP-TGF-b1 pre-
pro-protein (EYFP-LAP). Cells transfected with this construct
retained cytoplasmic EYFP but secreted LAP without the
EYFP, hence without sterical alterations (Figure 5A). Only
EYFP-positive CHO-LTBP-1 cells accumulated extracellular
LAP (Figure 5A). Western blotting confirmed the presence of
EYFP in extracts from EYFP-LAP-transfected CHO-LTBP-1
cells and its absence from conditioned medium (Figure 5B).
Importantly, tMLEC cells reported high levels of TGF-b1
in heat-activated conditioned medium (Figure 5C). Hence,
LAP-TGF-b1 was deposited as LLC onto the substrate after
intracellular cleavage of EYFP and TGF-b1 could be activated.
We also attempted to add EGFP to the TGF-b1 moiety
(TGF-b1-EGFP) (Figure 5). Although several tests suggested
that TGF-b1-EGFP SLC was produced and secreted together
with LTBP-1, the EGFP-tagged TGF-b1 was not adequately
matured and was not released from the LLC (Figures 5 and
S5). These constructs were not pursued.
For AFM stretching experiments, the position of EYFP-LAP-
positive cells with abundant LTBP-1-mRFP (Figure 6A) was
recorded using coverslips with grids. Cells and fibrils were
then DOC extracted and LTBP-1-mRFP was relocalized.
Pulling on the LTBP-1-mRFP-LAP complex with a LAP anti-
body-coated AFM probe produced multiple unfolding events
Figure 3. Unfolding Single Molecules of LTBP-1
(A) Wild-type CHO cells express neither LAP nor LTBP-1,
in contrast to LTBP-1 expression by CHO cells trans-
fected with LTBP-1 or LTBP-1-mRFP.
(B) After DOC extraction of LTBP-1-mRFP-transfected
CHO cells, the remaining insoluble ECM stains positive
for LTBP-1.
(C) 3D rendering of confocal sections of LTBP-1-mRFP-
transfected CHO cells shows LTBP (red) fibrillar organi-
zation between cells (nuclei in blue) and patches on the
substrate level.
Scale bars represent 10 mm.
(D) Force-extension profiles obtained after probingDOC-
extracted LTBP-1-mRFP-positive ECM patches with
AFM tips covalently coated with LTBP-1 antibodies
were fitted with a worm-like chain model (black lines).
(E) DLc were summarized in histograms and event popu-
lations (red dashed lines) were discriminated; maxima
are indicated with arrowheads.
(F) DLc-force pairs in LTBP-1 were plotted in color-
coded contour plots.
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at 10.8 6 2.4 nm, 17.2 6 4.2 nm, 27.8 6 7.5 nm, and 46.9 6
20.0 nm (Figure 6C). In unfolding forces histograms, we de-
tected four populations at 32.6 6 12.9 pN, 68.7 6 23.7 pN,
141.16 45.4 pN, and 268.26 40.4 pN (Figure S1). Comparison
of distributions of LLC with individual LLC components is
provided in Figure S2.
Summarizing data in DLc-force pair plots revealed two
dominant populations at 14.8 nm/61.2 pN and 18.8 nm/43.7
pN (Figure 6D). Filtering for LAP/SLC domain unfolding events
(Figure 6E) delivered two event populations corresponding
to the a1 helix domain (11.4 nm/51.2 pN) and to the whole
straitjacket (18.3 nm/38.6 pN) (Figure 2A; Table S1). Control
experiments with LAP antibody- (Figure 6F) or nonspecific
antibody (unpublished data) -coated AFM probes did not
reveal any of these populations in LTBP-1 ECM.
It has been predicted from the SLC crystal structure that
straitjacket opening will necessarily lead to TGF-b1 release
[25]. If this were true, TGF-b1 should be released into the
medium upon force application to single LLC complexes
through the LAP moiety. Because TGF-b1 could not be acti-
vated from SLC formed with fluorescently tagged TGF-b1(Figures 5 and S5) and because one single
TGF-b1molecule is below the detection sensi-
tivity of tMLEC reporter cells, we employed
a different pulling assay. Ferromagnetic beads
were coated with LAP antibody or with re-
combinant integrin avb6, the most potent
LAP-binding and TGF-b1-activating integrin
[16, 34]. Bovine serum albumin (BSA)-coated
microbeads were used as controls. Microbe-
ads were adsorbed onto DOC-extracted
LLC-rich ECM. All controls with no force
application exhibited low levels of active
TGF-b1 in the medium, reaching 15%–20%
of total TGF-b1 available in the ECM (Fig-
ure 7A). Applying magnetic force to BSA-
coated beads led to the release of active
TGF-b1 of w25% of total TGF-b1 (Figure 7A),
probably because of nonspecific shear
forces that are able to activate TGF-b1 [35].
In contrast, pulling anti-LAP- and avb6integrin-coated beads released 1.7- to 2.2-fold higher quanti-
ties of active TGF-b1 (w40% and 50%of total TGF-b1, respec-
tively) compared with BSA-coated magnet-pulled beads
(Figure 7A).
Discussion
Wehave recently established that transmission of cell contrac-
tile forces to LAP via integrins activates latent TGF-b1 reser-
voirs from noncompliant ECM [21]. We here demonstrated at
the single-molecule level that pulling on LAP will induce
conformational changes, attributed to TGF-b1 activation. (1)
Application of force induces LAP domain unfolding with
distinct profiles for LAP and SLC. (2) The latency lasso domain
of the LAP straitjacket is one key element inmechanical activa-
tion of TGF-b1. (3) A second key element is the TGF-b1/LTBP-1
binding a1 helix. (4) Anchoring of the SLC to LTBP-1 to form the
LLC favors the simultaneous straightening of latency lasso and
a1 helix and full opening of the straitjacket. (5) Lower forces
were required to unfold SLC in the LLC, indicating that
LTBP-1 acts as a leverage point that decreases the force
threshold for TGF-b1 activation from LAP.
Figure 4. Production of LLC for AFMPulling Experiments
(A) Wild-type CHO cells and CHO cells transfected with
LTBP-1 do not secrete TGF-b1 into the ECM. Upon co-
transfection of LAP-TGF-b1 with LTBP-1, LLC is formed
as shown by colocalization of LTBP-1 (red) and TGF-b1
(green).
(B) Immunofluorescence staining of LAP (red), TGF-b1
(green), and LTBP-1 (blue) after DOC extraction of CHO
cells coexpressing LTBP-1 and LAP-TGF-b1 demon-
strates patches of LLC on the substrate.
(C and D) Confocal optical slices of the ECM top to
bottom (C) and orthogonal projections of confocal recon-
structions of the LLC patches (D) elucidated the vertical
organization of the proteins.
Scale bar represents 10 mm.
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that TGF-b1 activation involves conformational changes in
the N-terminal portion of LAP, which confers latency by
binding to TGF-b1 [25, 36–40]. The recently published 3D
structure of the SLC revealed two structures that interact
with TGF-b1 in this LAP region: the a1 helix and the latency
lasso, together forming a straitjacket that traps TGF-b1 [25]
(Figure 2A). In contrast to the remaining LAP molecule, which
is packed in a force-resistant structure, the a1 helix and the
latency lasso are ill-suited to withstand force and would be
most susceptible to be unfold upon mechanical stretch [25].
Our pulling experiments with recombinant proteins demon-
strate that both the a1 helix and latency lasso are central in
mechanical activation of latent TGF-b1. First, a domain length
corresponding to the 17 aa latency lasso is detected only when
TGF-b1 associates with LAP, suggesting that TGF-b1 stabi-
lizes the conformation of this domain in the SLC. Second,
unfolding of the 28 aa a1 helix domain in SLC requires forces
w2-fold higher than in the empty LAP (Table S1). Both findings
are consistent with the concept that interactions linking struc-
tural motifs in strategic positions generally alter protein unrav-
eling characteristics [41]. TGF-b1 seems to stabilize the SLC
by reinforcing the a1 helix, which holds TGF-b1 in the LAP.
Their different susceptibility to mechanical stretch indicates
the potential of the a1 helix and latency lasso as force sensors.
In vivo, SLC binding to LTBP-1 in the ECM establishes me-
chanical resistance to integrin-mediated cell pulling [16, 21].
By coexpressing the LLC components via mammalian cells,
we provided a simplified yet physiologically relevant ECM
model for AFM experiments. Most remarkably, events corre-
sponding to unfolding of the entire straitjacket were predomi-
nant in the LLC but occurred with low frequency in the SLC.
This lever effect of LTBP-1 can be explained by the overlap
of the TGF-b1 and LTBP-1 binding epitopes close to the N
terminus of LAP (Arg45-Leu59) in the a1 helix region [40].
This leverage anchoring point on the LTBP-1 has important
implications for the force needed to activate TGF-b1 fromECM-bound LLC. The presence of the LTBP-1
lever increases the probability of unfolding
the entire straitjacket, by lowering full strait-
jacket unfolding forces (w40 pN) below the
forces needed for unfolding its latency lasso
(w50 pN) and a1 helix subdomains (w80 pN)
(Table S1). Our results further indicate that
adsorption of SLC to ECM components other
than LTBP-1 [18] does not lower the full strait-
jacket unfolding force and thus will not have
the same leverage effect.Our data together with the crystal structure of SLC indicate
full opening of the LAP straitjacket upon LLC pulling, support-
ing an ‘‘all-or-nothing’’ model of TGF-b1 release upon acti-
vation (Figure 7B). The question remains how mechanical
TGF-b1 activation can be regulated in such a model. Because
straitjacket opening and TGF-b1 release from the LLC need to
overcome a pulling force threshold, regulation probably
occurs at the level of force build-up. This control can imply
modulation of (1) intracellular force development by actin/
myosin interaction, (2) integrin binding affinity and strength
by feedback force or chemical signals, and (3) ECM stiffness
and resistance to integrin pulling. All these premises are in
agreement with our previous observation that TGF-b1 activa-
tion is modulated by the level of cell-generated tension and
that ECM stiffness has to exceed a threshold to result in
mechanical TGF-b1 activation [21]. A compliant ECM does
not oppose cell-derived contractile forces and LAP unfolding
will be impaired, regardless of the cell contraction strength
(Figure 7B). A stiff ECM, however, provides the necessary
resistance to promote a full conformational change of the
LAP and TGF-b1 release by cell contraction (Figure 7B).
Unfolding the TGF-b1 straitjacket in the LLC was achieved
with pulling forces of w40 pN, which is in the range of forces
transmitted by single integrins (tens of pN up to 165 pN)
[28–31, 42]. Hence, one integrin would be sufficient to transmit
the force required to unfold the latent TGF-b1 structure. These
force values, obtained with single-molecule AFM, are different
from values obtained from microbead pulling experiments,
which typically deliver at least 10- to 100-fold lower integrin
forces [43, 44]. This discrepancy partly originates from the
fact that microbead experiments average force values over
the number of possible integrin-ligand interactions on the
bead surface. However, not all integrins on the bead surface
will be bound, leading to a systematic underestimation of
single integrin force. Importantly, magnetic microbeads can
exert the forces that are needed to directly activate and release
TGF-b1 from a LLC ECM in our experiments, demonstrating for
Figure 5. Production and Characterization of Fluorescently Detectable LLC
(A) CHO-LTBP-1 cells were transfected with TGF-b1-EGFP (left) and immunostained for extracellular EGFP (green) and LAP (red). Anti-LAP immunostaining
of nonpermeabilized CHO-LTBP-1 cells transfected with EYFP-LAP revealed extracellular LAP, preserved after DOC extraction. EYFP was detected within
cells and lost only after DOC treatment (right). Scale bar represents 10 mm.
(B) Immunoblotting total cell extracts from TGF-b1-EGFP-transfected CHO-LTBP-1 cells with EG/YFP antibodies revealed bands at the expectedmolecular
weight for LLC-EGFP (w240 kDa), SLC-EGFP (w80 kDa), and TGF-b1-EGFP (w40 kDa); only a w240 kDa band (LLC-EGFP) was present in blots from
conditioned medium. Immunoblotting extracts from EYFP-LAP-transfected CHO-LTBP-1 cells revealed a strong band at the expected molecular weight
of EYFP-LAP (w70 kDa) and weaker bands corresponding to SLC-EYFP (w80 kDa) and LLC-EYFP (w240 kDa). Lanes: (1) control; (2) EGFP; (3) TGF-b1;
(4) TGF-b1-EGFP; (5) EYFP-LAP.
(C) TGF-b1 activity was determined with tMLEC reporter cells incubated with conditioned media of the same cells. Shown are means 6 SD.
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Another important finding of our study is that pulling on the
SLC portion of the LLC can lead to unfolding events in the
LTBP-1, as seen from comparison with profiles obtained from
pulling LTBP-1 in the absence of SLC. The LTBP-1 backbone
comprises repeats of epidermal growth factor (EGF)-like
domains interspersed with 8-Cys repeats, of which the third
8-Cys repeat binds LAP via disulfide bonds (Figure 1A) [45].
The average lengthof onecompletely unfoldedEGF-like repeat
is 15.2–16.0 nm (38–40 aa) and the average length of one 8-Cys
domain is 21.6 nm (54 aa) [46]. Thus, pulling on SLC in LLC
appears to unfold EGF-like domains in the LTBP-1 (e.g., at
14.8 nm/61.2 pN). Althoughwe didmeasure frequent unfolding
events in LTBP-1 that could correspond to 8-Cys domains
(e.g., at 22.6 nm/68 pN), we did not observe such events
when probing the LLC. Unfolding of 8-Cys domains is unlikely,
possibly because of internal domain disulfide bonds that are
difficult to unfold [33], acting as amechanical barrier to prevent
the disassembly of the TGF-b1-binding domain upon integrin
pulling. Finally, the two maxima with longer DLc observed in
both LTBP-1 and LLC (27.8 6 7.5 nm and 46.9 6 20.0 nm)
may correspond to partially unfolded LTBP-1 domains,
because they exhibit lower resistance to stretch and their
length consists of a multiple of the EGF-like domain length.
In summary, we have characterized the mechanical stress
involved inTGF-b1activation fromSLCandLLCat themolecularlevel anddemonstratedTGF-b1 releaseupon force transmission
to LAP. A force of >40 pN is required to unfold LAP domains
critical forprovidingTGF-b1 latency in theLLC. It is thusconceiv-
able that mechanical activation of latent TGF-b1 is restricted
to integrins with high binding affinity to LAP, to cells that can
transmit considerable force to the LAP, and to a sufficiently rigid
ECM.Hence,pharmacological interferencewitheither factorwill
affect TGF-b1 activation. Importantly, therapeutic strategies to
block harmful TGF-b1 activity in fibrosis or cancer progression
could already be effective when integrin binding and cell con-
traction are decreased below the TGF-b1 activation threshold
without completely blocking either process.
Experimental Procedures
Plasmid Constructs, Cell Culture, and Transfection
To allow live detection, we produced fluorescent fusionproteins of all human
LLCcomponents (seeSupplemental Information); EYFP-LAP-b1 (EYFP-LAP)
was commercially obtained (IOH4479-pdEYFP-C1amp, imaGenes GmbH,
Germany). Recombinant proteins were expressed in Chinese hamster ovary
(CHO K1) cells after transient transfection via JetPei (PolyPlus-transfection
SA, France) according to manufacturer’s instructions. CHO cells, stably
transfected with LTBP-1S (CHO-LTBP-1), were a kind gift from D. Rifkin
[16]. We used 10 mg/ml recombinant SLC/LAP to coat mica surfaces (R&D
Systems, MN). Lab reagents were obtained from Sigma (Switzerland).
ECMPreparation, Immunofluorescence Staining, and Light Microscopy
ECM containing different LLC components was produced by plating trans-
fected CHO cells for 7 days on glass coverslips or on 35mm ‘‘m-dishes’’ with
Figure 6. Unfolding of LLC
(A) CHO cells were cotransfected with LTBP-1-mRFP
(red) and EYFP-LAP (green). Scale bar represents 20 mm.
(B) The force-extension profiles obtained after stretching
LLC with anti-LAP antibody-coated AFM probes were
fitted with a worm-like chain model (black lines).
(C) DLcs were summarized in histograms and event pop-
ulations (red dashed lines) were discriminated; maxima
are indicated with arrowheads.
(D) DLc-force pairs in LLC were plotted in a color-coded
contour plot.
(E) All force-extension curves from LLC were analyzed
for DLcs that would correspond to the length of domains
predicted to be critical for TGF-b1 storage in LAP (see
Figure 2). All LLC unfolding events falling in either of
the search windows defined by the domain theoretical
DLc (dashed lines) 6 10% (dotted lines) were plotted
in a bivariate DLc-force contour map.
(F) No LAP domains were detected in LTBP-1 when
pulled with LAP antibodies (control), demonstrating the
specificity of LLC measurements.
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2052grid (IBIDI GmbH, Germany) in serum-free conditions. Pure ECM was
obtained by removing cells with ice-cold desoxycholate (DOC) buffer
(0.5% DOC, 1% NP-40, 150 mM NaCl in 10 mM Tris-HCl [pH 8.0]) for
10 min, followed by washing with PBS. Only protein layers intimate to
the culture surface were preserved after DOC extraction of CHO cells. We
have preferred this approach over using purified LTBP-1 and LLC to
preserve proper folding and conformation of protein complexes and to
avoid loss of TGF-b1 from the LLC during purification. Extracellular LLC
components on whole-cell preparations were immunostained by incubating
living cells with the corresponding primary antibodies (2 hr, 37C), followed
by fixation and incubation with secondary antibodies omitting permeabiliza-
tion. LLC components from fresh DOC-extracted samples were stained
similarly. Fluorescence imaging was performed with a SP2 Leica AOBS
inverted confocal microscope (Leica Microsystems GmbH, Germany) and
deconvoluted with HuygensPro (SVI, The Netherlands).
TGF-b1 Activity Measurements
To measure active TGF-b1, tMLEC reporter cells [47] were incubated with
TGF-b1-containing solutions for 18 hr. To measure total TGF-b1, samples
were heat treated 10min at 80C [21]. tMLECwere then lysed and luciferase
activity was quantified with a luciferin substrate (Promega, WI) in a Centro
LB Luminometer (Berthold Technologies, Germany). TGF-b1 levels are ex-
pressed asmean6SDof at least three independent experiments performed
in duplicate.
AFM-Force Spectroscopy and Statistical Analysis
Gold-coated Si3N4 cantilevers (Microlevers, Veeco, CA) with an average
measured spring constant of 0.045 6 0.014 N/m were coated with
20 mg/ml of monoclonal LAP or LTBP-1 antibody (for details see Supple-
mental Information). AFM measurements were performed with the Nanowi-
zard II (JPK Instruments, Germany) mounted onto the stage of a Zeiss 200M
inverted epifluorescencemicroscope (Carl Zeiss, Germany).We set the pull-
ing speed at 200 nm/s, corresponding to a loading rate of w10,000 pN/s,
comparablewith similar studies [28–31]. All force-extension curves showingprotein unfolding events upon pulling were analyzed.
The contour length (Lc) for each unfolding event in the
force-extension AFM curves was obtained via a worm-













where kB is Boltzmann’s constant, T is temperature, p is
persistence length (fixed at 0.4 nm), and x is extension.
Curves were fitted with the JPK Imaging Processing
software (JPK Instruments).
All data points for DLc and unfolding forces were
summarized in frequency histograms (percent of all
events) and provided with Gaussian fits (Supplemental
Information) [48]. In text, maxima of the Gaussian fittings are expressed 6
SD. To directly relate force and DLc for every unfolding event, pairs of
DLc and force were plotted on three-dimensional color-coded maps
(Supplemental Information) [49]. To better determine the force necessary
to unfold SLC/LAP key domains, we filtered the curves that presented
events compatible with the lengths of these protein domains (Supplemental
Information). Filtered data were displayed in bivariate color-coded plots of
DLc over force. All data analysis was performed with MatLab v 7.9 (The
MathWorks, MA).
Force Application via Ferromagnetic Microbeads
To directly demonstrate force-mediated release of active TGF-b1 from LLC
ECM, we used ferric oxide microparticles (Sigma) and a permanent ceramic
magnet. Beads were coated with 10 mg of LAP antibodies (R&D Systems),
recombinant human integrin avb6 (R&D Systems), or BSA (BioShop Canada
Inc., ON). Beads were then washed in PBS and resuspended in fresh serum-
free tMLECmedium. DOC-extracted ECMof LLC-expressing cells was incu-
bated with coated beads (30 min) before multidirectional force was applied
with the magnet. TGF-b1 released from LLC was measured with tMLEC
reporter cells.
Supplemental Information
Supplemental Information includes Supplemental Experimental Proce-
dures, five figures, one table, and one movie and can be found with this
article online at doi:10.1016/j.cub.2011.11.037.
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